Home
HelpTest Code UROVY UroVysion for Detection of Bladder Cancer, Urine
Reporting Name
UroVysion (R) for Bladder CancerUseful For
Monitoring for tumor recurrence in patients with a history of urothelial carcinoma involving the bladder or upper urinary tract
Assessing patients with hematuria for urothelial carcinoma
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
VariesSpecimen Required
Necessary Information
1. Specimen source is required on request form (ie voided, catheterized, bladder washing).
2. Provide fixative, source, reason for referral (evaluate for urothelial carcinoma or hematuria) and status of diagnosis (known previous diagnosis or suspected/unknown).
Specimen Required
Specimen Type: Urine
Sources: Voided urine, catheterized urine, bladder washings, stoma collections, ureteral brushings or washings, renal pelvic brushings or washings
Supplies: FISH for Urothelial Carcinoma Urine Collection Kit (T509)
Container/Tube:
Preferred: FISH for Urothelial Carcinoma in Urocyte Urine Collection Kit
Acceptable: 70% ethanol, PreservCyt, CytoLyt, ThinPrep UroCyte (UroCyte PreservCyt Solution)
Specimen Volume: 30 mL
Collection Instructions:
1. Follow instructions included with Urocyte Urine Collection Kit.
2. If kit is not used, submit a random urine specimen with an equal volume of 70% ethanol, PreservCyt, or CytoLyt.
Specimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Refrigerated (preferred) | ||
| Ambient | |||
Special Instructions
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Friday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88120
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FUROC | UroVysion (R) for Bladder Cancer | 82251-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 54674 | Result Summary | 50397-9 |
| 54675 | Result | 82251-0 |
| 54676 | Interpretation | 69047-9 |
| 54677 | Reason for Referral | 42349-1 |
| 54678 | Specimen | 31208-2 |
| 54679 | Source | 31208-2 |
| 54680 | Released By | 18771-6 |
Clinical Reference
1. Halling KC, Kipp BR: Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008:15(5):279-286. doi: 10.1097/PAP.0b013e3181832320.
2. Gayed BA, Seideman C, Lotan Y: Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013 Oct;190(4):1181-1186. doi: 10.1016/j.juro.2013.03.117
Method Description
Urinary cells are harvested, fixed, and placed on a slide. The UroVysion probe set, which contains fluorescently labeled DNA probes specific to the centromeres of chromosomes 3, 7, 17, and to the 9p21 locus is hybridized to the cells on the slide. The slide is washed and counterstained with 4',6-diamidino-2'-phenylindole dihydrochloride (DAPI) stain. Fluorescence microscopy with unique band filters is then used to scan the slide for atypical cells (eg, cells with nuclear enlargement or irregularity). These cells are assessed for gains of chromosomes (3, 7, 17) or homozygous 9p21 deletion. If the number of cells with chromosomal gains (polysomy or trisomy) or homozygous 9p21 deletion observed on scanning is sufficient to consider the test result positive, the percentage of transitional cells with polysomy, trisomy, or homozygous 9p21 deletion is determined.(Halling KC, King W, Sokolova IA, et al: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775; Sokolova IA, Halling KC, Jenkins RB, et al: The development of a multi-target, multi-color fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123. doi: 10.1016/S1525-1578(10)60625-3.)
Report Available
7 to 10 daysReject Due To
| Unfixed specimens 48 hours after collection | Reject |
Method Name
Fluorescence In Situ Hybridization (FISH) using DNA Probes
Forms
1. Pathology/Cytology Information (T707) in Special Instructions
2. If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.